Report
Evotec AG : Declining biopharma R&D productivity opens up opportunities for EVT
Declining R&D productivity in the biopharma segment translates into significant opportunities for EVT. The Innovate segment provides solutions for large pharma players short on innovation, while the Execute segment addresses players that have good innovation but lack capacity. Recently acquired Aptuit, especially its INDiGO projects, provides an additional growth driver. Although Q1Â 18 was unimpressive, we expect Evotec to deliver reassuring quarters in the balance of the year dr...
Underlying
Evotec AG ADS
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.